110 East 59th Street
Fax: (212) 883-2260
60 articles with Royalty Pharma
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today its collaboration with Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, to expand MSCI’s thematic index suite with the launch of new indexes
– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.
- Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise
New Ventures Funds , a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX). The company raised $2.18 billion through the sale of 77,681,670 of its Class A ordinary shares priced at $28.00 per share
Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.
Royalty Pharma announced that it has acquired Massachusetts General Hospital's royalty interest in Entyvio for $94 million.
Royalty Pharma announced today that Chris Hite has agreed to join the Company as Executive Vice President and Vice Chairman.
Royalty Pharma Announces Appointment of George Grofik as SVP, Head of Investor Relations and Communications
Royalty Pharma, the largest acquiror of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, announced today that George Grofik has been appointed Senior Vice President, Head of Investor Relations and Communications.
Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme
Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.
Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement
Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced funding agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, in aggregate, could bring in up to $270 million in capital, significantly strengthening Epizyme’s financial position and extending its operating runway into at least 2022.
- Royalty Pharma is pleased to announce that Susannah Gray has been named Executive Vice President – Finance & Strategy, Terrance Coyne has been promoted to Chief Financial Officer, and Kristin Stafford has been promoted to Chief Accounting Officer.
Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.
Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million
Royalty Pharma acquires approximately 2% royalty rights on global annual net sales of rimegepant and BHV-3500 from Biohaven for $100 million
Royalty Pharma Partners With Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase